SCHEMBL7035192

SCHEMBL7035192

CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccc(O)cn1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 16/20 0.73
RXRA P19793 2/20 0.65
RARG P13631 1/20 0.65
PPARA Q07869 4/20 0.61
CYP3A4 P08684 2/20 0.56
FFAR1 O14842 3/20 0.53
MPC2 O95563 1/20 0.50
CYP2C8 P10632 1/20 0.50
CYP2C9 P11712 1/20 0.50
MEN1 O00255 1/20 0.49
ALDH1A1 P00352 1/20 0.49
TP53 P04637 1/20 0.49
CYP1A2 P05177 1/20 0.49
MAPT P10636 1/20 0.49
HPGD P15428 1/20 0.49
ALOX15 P16050 1/20 0.49
TSHR P16473 1/20 0.49
KMT2A Q03164 1/20 0.49
HSD17B10 Q99714 1/20 0.49
TDP1 Q9NUW8 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13850262 0.90 PPARG (0.73) PPARGRXRARARGPPARACYP3A4
SCHEMBL13524842 0.90 PPARG (0.73) PPARGRXRARARGPPARACYP3A4
SCHEMBL13847850 0.89 PPARG (0.72) PPARGRXRARARGPPARACYP3A4
SCHEMBL13847851 0.88 PPARG (0.71) PPARGRXRARARGPPARACYP3A4
SCHEMBL13850179 0.88 PPARG (0.71) PPARGRXRARARGPPARACYP3A4
SCHEMBL7033344 0.88 PPARG (0.73) PPARGRXRARARGPPARACYP3A4
SCHEMBL13847858 0.87 PPARG (0.69) PPARGRXRARARGPPARACYP3A4
SCHEMBL7507856 0.87 PPARG (0.69) PPARGRXRARARGPPARACYP3A4
SCHEMBL13847855 0.85 PPARG (0.66) PPARGRXRARARGPPARACYP3A4
Rosiglitazone SCHEMBL2355017 0.84 PPARG (1.00) PPARGRXRARARGPPARACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030125358-A1 Pharmaceutical compositions containing thiazolidinedione derivatives and process for their preparation SMITHKLINE BEECHAM P.L.C. 2003-07-03 US claimed
EP-1202991-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING THIAZOLIDINEDIONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION SMITHKLINE BEECHAM PLC (GB) 2002-05-08 EP claimed
WO-2001012628-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING THIAZOLIDINEDIONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION SMITHKLINE BEECHAM P.L.C. (GB) 2001-02-22 WO claimed
US-20030125358-A1 Pharmaceutical compositions containing thiazolidinedione derivatives and process for their preparation SMITHKLINE BEECHAM P.L.C. 2003-07-03 US disclosed
EP-1202991-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING THIAZOLIDINEDIONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION SMITHKLINE BEECHAM PLC (GB) 2002-05-08 EP disclosed
WO-2001012628-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING THIAZOLIDINEDIONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION SMITHKLINE BEECHAM P.L.C. (GB) 2001-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125358-A1 Pharmaceutical compositions containing thiazolidinedione derivatives and process for their preparation TNNT2, FABP3, TNNI3 PPARG 31/4885RXRA 975/4885RARG 500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.